News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,880 Results
Type
Article (452)
Press Release (2428)
Section
Business (669)
Career Advice (4)
Deals (208)
Drug Development (120)
FDA (183)
Job Trends (46)
News (1433)
Policy (422)
Tag
Academia (2)
Africa (12)
Allergies (1)
Alliances (120)
Alzheimer's disease (1)
Approvals (183)
Asia (191)
Australia (13)
Best Places to Work (14)
Biosimilars (4)
C2C Services and Suppliers (39)
California (2)
Career advice (4)
Clinical research (100)
COVID-19 (10)
Diagnostics (8)
Earnings (307)
Europe (620)
Events (194)
Executive appointments (1)
FDA (183)
GLP-1 (3)
Government (47)
Grass and pollen (1)
Healthcare (16)
Hotbed/Location (1401)
Infectious disease (10)
IPO (50)
Job creations (32)
Job search strategy (4)
Layoffs (7)
Legal (236)
Medical device (10)
Medtech (10)
Mergers & acquisitions (158)
Neuroscience (1)
New York (1)
NextGen Class of 2024 (19)
Non-profit (4)
Northern California (2)
Opinion (6)
Pennsylvania (1)
People (203)
Phase I (19)
Phase II (43)
Phase III (53)
Postmarket research (7)
Preclinical (3)
Real estate (11)
Regulatory (151)
Research institute (2)
South America (12)
Startups (8)
United States (5)
Date
Last 30 days (1)
Last 365 days (49)
2024 (29)
2023 (51)
2022 (349)
2021 (262)
2020 (258)
2019 (159)
2018 (162)
2017 (189)
2016 (219)
2015 (274)
2014 (121)
2013 (100)
2012 (137)
2011 (97)
2010 (89)
2,880 Results for "mylan".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.
June 22, 2023
·
5 min read
Business
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.
June 22, 2023
·
6 min read
Policy
Lawsuits Galore: J&J, BMS, GSK, Mylan and Others
Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.
May 25, 2022
·
2 min read
·
Alex Keown
Genetown
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
December 19, 2023
·
4 min read
Drug Development
Appeals Court Upholds Decision for Mylan Generic of Biogen MS Drug
The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen’s Multiple Sclerosis (MS) drug, Tecfidera.
March 17, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
Policy
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.
October 30, 2020
·
13 min read
Business
Mylan Board Appoints Robert J. Coury As Executive Chairman of Mylan N.V.
The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced the appointment of Robert J. Coury , previously chairman of the Mylan Board, to the position of executive chairman of Mylan. Given the unprecedented current operating environment due to the COVID-19 pandemic, the extensive ongoing activity
April 15, 2020
·
12 min read
Pharm Country
Mylan Shareholders Overwhelmingly Approve Proposed Combination with Upjohn
Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders.
June 30, 2020
·
12 min read
Deals
FTC Clears Merger between Mylan and Pfizer’s Upjohn Business
Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.
November 4, 2020
·
3 min read
·
Alex Keown
Pharm Country
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitu
November 16, 2020
·
5 min read
1 of 288
Next